Recombinant vaccinia DIs expressing simian immunodeficiency virus gag and pol in mammalian cells induces efficient cellular immunity as a safe immunodeficiency virus vaccine candidate

Microbiology and Immunology

Volumn 50, Issue 12, 2006, Pages 989-1000

  Okamura, Tomotaka ^a,b   Someya, Kenji ^a   Matsuo, Kazuhiro ^a   Hasegawa, Atsuhiko ^b   Yamamoto, Naoki ^a   Honda, Mitsuo ^a  

^a NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^b NIHON UNIVERSITY   (Japan)

Author keywords

Antigen production; HIV vaccine; Recombinant vaccinia DIs

Indexed keywords

GAG PROTEIN; GAMMA INTERFERON; POL PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIGEN SPECIFICITY; ARTICLE; CELL LINE; CELLULAR IMMUNITY; CHICK EMBRYO; CONTROLLED STUDY; CYTOPLASM; ELECTRON MICROSCOPY; FEMALE; FIBROBLAST; GENE DELETION; GENE INSERTION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MAMMAL CELL; MOUSE; NONHUMAN; PROTEIN EXPRESSION; SIMIAN IMMUNODEFICIENCY VIRUS; VACCINIA VIRUS; VIROGENESIS; VIRUS RECOMBINANT; VIRUS REPLICATION; VIRUS STRAIN;

HUMAN IMMUNODEFICIENCY VIRUS; MAMMALIA; SIMIAN IMMUNODEFICIENCY VIRUS; VACCINIA VIRUS;

EID: 33845800339     PISSN: 03855600     EISSN: 13480421     Source Type: Journal    
DOI: 10.1111/j.1348-0421.2006.tb03867.x     Document Type: Article

References (46)

1. Amara, R.R., Smith, J.M., Staprans, S.I., Montefiori, D.C., Villinger, F., Altman, J.D., O'Neil, S.P., Kozyr, N.L., Xu, Y., Wyatt, L.S., Earl, P.L., Herndon, J.G., McNicholl, J.M., McClure, H.M., Moss, B., and Robinson, H.L. 2002. Critical role for Env as well as Gag-Pol in control of a simian-human immunodeficiency virus 89.6P challenge by a DNA prime/recombinant modified vaccinia virus Ankara vaccine. J. Virol. 76: 6138-6146.
2. Amara, R.R., Villinger, F., Altman, J.D., Lydy, S.L., O'Neil, S.P., Staprans, S.I., Montefiori, D.C., Xu, Y., Herndon, J.G., Wyatt, L.S., Candido, M.A., Kozyr, N.L., Earl, P.L., Smith, J.M., Ma, H.L., Grimm, B.D., Hulsey, M.L., Miller, J., McClure, H.M., McNicholl, J.M., Moss, B., and Robinson, H.L. 2001. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 292: 69-74.
3. Ami, Y., Izumi, Y., Matsuo, K., Someya, K., Kanekiyo, M., Horibata, S., Yoshino, N., Sakai, K., Shinohara, K., Matsumoto, S., Yamada, T., Yamazaki, S., Yamamoto, N., and Honda, M. 2005. Priming-boosting vaccination with recombinant Mycobacterium bovis bacillus Calmette-Guerin and a nonreplicating vaccinia virus recombinant leads to long-lasting and effective immunity. J. Virol. 79: 12781-12789.
4. Antoine, G., Scheiflinger, F., Dorner, F., and Falkner, F.G. 1998. The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses. Virology 244: 365-396.
5. Barouch, D.H., Santra, S., Schmitz, J.E., Kuroda, M.J., Fu, T.M., Wagner, W., Bilska, M., Craiu, A., Zheng, X.X., Krivulka, G.R., Beaudry, K., Lifton, M.A., Nickerson, C.E., Trigona, W.L., Punt, K., Freed, D.C., Guan, L., Dubey, S., Casimiro, D., Simon, A., Davies, M.E., Chastain, M., Strom, T.B., Gelman, R.S., Montefiori, D.C., Lewis, M.G., Emini, E.A., Shiver, J.W., and Letvin, N.L. 2000. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science 290: 486-492.
6. Brenchley, J.M., Karandiker, N.J., Betts, M.R., Ambrozak, D.R., Hill, B.J., Crotty, L.E., Casazza, J.P., Kuruppu, J., Migueles, S.A., Connors, M., Roederer, M., Douek, D.C., and Koup, R.A. 2003. Expression of CD57 defines replicative senescence and antigen induced apoptotic death of CD8+ T cells. Blood 101: 2711-2720.
7. Carroll, M.W., and Moss, B. 1997. Host range and cytopathogenicity of highly attenuated MVA strain of vaccinia virus: propagation and generation of recombinant viruses in nonhuman mammalian cell line. Virology 238: 198-211.
8. Earl, P.L., Wyatt, L.S., Montefiori, D.C., Bilska, M., Woodward, R., Markham, P.D., Malley, J.D., Vogel, T.U., Allen, T.M., Watkins, D.I., Miller, N., and Moss, B. 2002. Comparison of vaccine strategies using recombinant env-gagpol MVA with or without an oligomeric Env protein boost in the SHIV rhesus macaque model. Virology 294: 270-281.
9. Fujii, R., and Minamitani, M. 1968. Virus infections with exanthema. Saishin Igaku 23: 1146-1155.
10. Garber, D.A., Silvestri, G., and Feinberg, M.B. 2004. Prospects for an AIDS vaccine: three big questions, no easy answers. Lancet Infect. Dis. 4: 397-413.
11. Hanke, T., Neumann, V.C., Blanchard, T.J., Sweeney, P., Hill, A.V., Smith, G.L., and McMichael, A. 1999. Effective induction of HIV-specific CTL by multi-epitope using gene gun in a combined vaccination regime. Vaccine 17: 589-596.
12. Hanke, T., McMichael, A.J., Mwau, M., Wee, E.G., Ceberej, I., Patel, S., Sutton, J., Tomlinson, M., and Samuel, R.V. 2002. Development of a DNAMVA/HIVA vaccine for Kenya. Vaccine 20: 1995-1998.
13. Harari, A., Petitpierre, S., Vallelian, F., and Pantaleo, G. 2004. Skewed representation of functionally distinct populations of virus-specific CD4 T cells in HIV-1-infected subjects with progressive disease: changes after antiretroviral therapy. Blood 103: 966-972.
14. Im, E.J., and Hanke, T. 2004. MVA as a vector for vaccines against HIV-1. Expert Rev. Vaccines 3: S89-97.
15. Ishii, K., Ueda, Y., Matsuo, K., Matsuura, Y., Kitamura, T., Kato, K., Izumi, Y., Someya, K., Ohsu, T., Honda, M., and Miyamura, T. 2002. Structural analysis of vaccinia virus DIs strain: application as a new replication- deficient viral vector. Virology 302: 433-444.
16. Kent, S.J., Zhao, A., Best, S.J., Chandler, J.D., Boyle, D.B., and Ramshaw, I.A. 1998. Enhanced T-cell immunogenicity and protective efficacy of a human immunodeficiency virus type 1 vaccine regimen consisting of consecutive priming with DNA and boosting with recombinant fowlpox virus. J. Virol. 72: 10180-10188.
17. Kitamura, T., and Kitamura, R. 1963. Interference with the growth of vaccinia virus by an attenuated mutant virus. J. Med. Sci. Biol. 16: 343-357.
18. Kitamura, T., Kitamura, Y., and Tagaya, I. 1967. Immunogenicity of an attenuated strain of vaccinia virus on rabbits and monkeys. Nature 215: 1187-1188.
19. Klausner, R.D., Fauci, A.S., Corey, L., Nabel, G.J., Gayle, H., Berkley, S., Haynes, B.F., Baltimore, D., Collins, C., Douglas, R.G., Esparza, J., Francis, D.P., Ganguly, N.K., Gerberding, J.L., Johnston, M.I., Kazatchkine, M.D., McMichael, A.J., Makgoba, M.W., Pantaleo, G., Piot, P., Shao, Y., Tramont, E., Varmus, H., and Wasserheit, J.N. 2003. Medicine. The need for a global HIV vaccine enterprise. Science 300: 2036-2039.
20. Liu, M., Acres, B., Balloul, J.M., Bizouarne, N., Paul, S., Slos, P., and Squiban, P. 2004. Gene-based vaccines and immunotherapeutics. Proc. Natl. Acad. Sci, U.S.A. 101 (Suppl 2): 14567-14571.
21. Mark Doherty, T. 2004. New vaccines against tuberculosis. Trop. Med. Int. Health 9: 818-826.
22. Matano, T., Kobayashi, M., Igarashi, H., Takeda, A., Nakamura, H., Kano, M., Sugimoto, C., Mori, K., Iida, A., Hirata, T., Hasegawa, M., Yuasa, T., Miyazawa, M., Takahashi, Y., Yasunami, M., Kimura, A., O'Connor, D.H., Watkins, D.I., and Nagai, Y. 2004. Cytotoxic T lymphocyte-based control of simian immunodeficiency virus replication in a preclinical AIDS vaccine trial. J. Exp. Med. 199: 1709-1718.
23. Matsuo, K., Nishino, Y., Kimura, T., Yamaguchi, R., Yamazaki, A., Mikami, T., and Ikuta, K. 1992. Highly conserved epitope domain in major core protein p24 is structurally similar among human, simian and feline immunodeficiency viruses. J. Gen. Virol. 73 (Pt 9): 2445-2450.
24. McCurdy, L.H., Larkin, B.D., Martin, J.E., and Graham, B.S. 2004. Modified vaccinia Ankara: potential as an alternative smallpox vaccine. Clin. Infect. Dis. 38: 1749-1753.
25. Meyer, H., Sutter, G., and Mayr, A. 1991. Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence. J. Gen. Virol. 72 (Pt 5): 1031-1038.
26. Minnigan, H., and Moyer, R.W. 1985. Intracellular location of rabbit poxvirus nucleic acid within infected cells as determined by in situ hybridization. J. Virol. 55 (3): 634-643.
27. Morita, M., Aoyama, Y., Arita, M., Amona, H., Yoshizawa, H., Hashizume, S., Komatsu, T., and Tagaya, I. 1977. Comparative studies of several vaccinia virus strains by intrathalamic inoculation into cynomolgus monkeys. Arch. Virol. 53: 197-208.
28. Moss, B. 1991. Vaccinia virus: a tool for research and vaccine development. Science 252: 1662-1667.
29. Moss, B. 1992. Vaccinia virus vectors. Biotechnology 20: 345-362.
30. Moss, B. 2001. Poxviridae, p. 2849-2883. In Fields, B.N., Knipe, D.M., and Howley, P.M. (eds), Fields virology, 4th ed, Lippincott-Raven, Philadelphia.
31. Moss, B. 2006. Poxvirus entry and membrane fusion. Virology 344: 48-54.
32. Moss, B., and Flexner, C. 1987. Vaccinia virus expression vectors. Annu. Rev. Immunol. 5: 305-324.
33. Moss, B., Fuerst, T.R., Flexner, C., and Hugin, A. 1988. Roles of vaccinia virus in the development of new vaccines. Vaccine 6: 161-163.
34. Moss, B., Smith, G.L., and Mackett, M. 1983. Use of vaccinia virus as an infectious molecular cloning and expression vector. Gene Amplif. Anal. 3: 201-213.
35. Patterson, L.J., Malkevitch, N., Venzon, D., Pinczewski, J., Gomes-Roman, V.R., Wang, L., Kalyanaraman, V.S., Markham, P.D., Robey, F.A., and Robert-Guroff, M. 2004. Protection against mucosal simian immunodeficiency virus SIV (mac251) challenge by using replicating adenovirus-SIV multigene vaccine priming and subunit boosting. J. Virol. 78: 2212-2221.
36. Sato, K. 1943. Contribution to the methods of obtaining and manipulating variola seed virus. Dojin Igaku Zasshi 17: 351.
37. Seth, A., Ourmanov, I., Schmitz, J.E., Kuroda, M.J., Lifton, M.A., Nickerson, C.E., Wyatt, L., Carroll, M., Moss, B., Venzon, D., Letvin, N.L., and Hirsch, V.M. 2000. Immunization with a modified vaccinia virus expressing simian immunodeficiency virus (SIV) Gag-Pol primes for an anamnestic Gag-specific cytotoxic T-lymphocyte response and is associated with reduction of viremia after SIV challenge. J. Virol. 74: 2502-2509.
38. Shiver, J.W., Fu, T.M., Chen, L., Casimiro, D.R., Davies, M.E., Evans, R.K., Zhang, Z.Q., Simon, A.J., Trigona, W.L., Dubey, S.A., Huang, L., Harris, V.A., Long, R.S., Liang, X., Handt, L., Schleif, W.A., Zhu, L., Freed, D.C., Persaud, N.V., Guan, L., Punt, K.S., Tang, A., Chen, M., Wilson, K.A., Collins, K.B., Heidecker, G.J., Fernandez, V.R., Perry, H.C., Joyce, J.G., Grimm, K.M., Cook, J.C., Keller, P.M., Kresock, D.S., Mach, H., Troutman, R.D., Isopi, L.A., Williams, D.M., Xu, Z., Bohannon, K.E., Volkin, D.B., Montefiori, D.C., Miura, A., Krivulka, G.R., Lifton, M.A., Kuroda, M.J., Schmitz, J.E., Letvin, N.L., Caulfield, M.J., Bett, A.J., Youil, R., Kaslow, D.C., and Emini, E.A. 2002. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 415: 331-335.
39. Someya, K., Ami, Y., Nakasone, T., Izumi, Y., Matsuo, K., Horibata, S., Xin, K.Q., Yamamoto, H., Okuda, K., Yamamoto, N., and Honda, M. 2006. Induction of positive cellular and humoral immune responses by a prime-boost vaccine encoded with simian immunodeficiency virus gag/pol. J. Immunol. 176: 1784-1795.
40. Someya, K., Cecilia, D., Nakasone, T., Ami, Y., Matsuo, K., Burda, S., Yamamoto, H., Yoshino, N., Kaizu, M., Ando, S., Zolla-Pazner, S., Okuda, K., Yamazaki, S., Yamamoto, N., and Honda, M. 2005. Vaccination with recombinant Mycobacterium bovis bacillus Calmette-Guerin (BCG)-Env V3 elicits neutralizing antibody-mediated protection in rhesus macaques against simian-human immunodeficiency virus with a homologous but not a heterologous V3 motif. J. Virol. 79: 1452-1462.
41. Someya, K., Xin, K.Q., Matsuo, K., Okuda, K., Yamamoto, N., and Honda, M. 2004. A consecutive priming-boosting vaccination of mice with simian immunodeficiency virus (SIV) gag/pol DNA and recombinant vaccinia virus strain DIs elicits effective anti-SIV immunity. J. Virol. 78: 9842-9853.
42. Stassi, M. 1973. Professional negligence of the health officer. Responsibility for insufficient antitetanic prevention. Minerva. Med. 64: 3805-3817.
43. Stickl, H., and Hochstein-Mintzel, V. 1971. Intracutaneous smallpox vaccination with a weak pathogenic vaccinia virus ("MVA virus ). Munch. Med. Wochenschr. 113: 1149-1153.
44. Tagaya, I. 1954. Studies on vaccinia hemagglutinin. I. On the production of vaccinia hemagglutinin in the developing chick embryo. Jpn. J. Med. Sci. Biol. 7: 39-48.
45. Tagaya, I., Kitamura, T., and Sano, Y. 1961. A new mutant of dermovaccinia virus. Nature 192: 381-382.
46. Tartaglia, J., Perkus, M.E., Taylor, J., Norton, E.K., Audonnet, J.C., Cox, W.I., Davis, S.W., van der Hoeven, J., Meignier, B., Riviere, M., Langnet, B., and Paoletti, E. 1992. NYVAC: a highly attenuated strain of vaccinia virus. Virology 188: 217-232.